Picard Medical

Picard Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Picard Medical (PMI) as of Nov 12, 2026 is 58.05 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 56.40 % — a change of 2.93% (higher).

FCF Conversion

58.05 %

YoY

2.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Picard Medical is 2025 58.05 % . FCF Conversion Rate (FCF/EBITDA) of Picard Medical was 2024 56.40 % . It decreases by 2.93% higher compared to the previous year.

The Picard Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
96.28 USD
Jan 1, 2023
68.35 USD
Jan 1, 2024
56.40 USD
Jan 1, 2025
58.05 USD
The Picard Medical FCF Conversion history
YEARFCF ConversionYoY
58.05 %+2.93%
56.40 %-17.49%
68.35 %-29.01%
96.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Picard Medical Stock analysis

What does Picard Medical do? Picard Medical Inc generates revenue through its wholly-owned subsidiary SynCardia Systems, LLC, which produces and sells the SynCardia TAH, the only FDA and Health Canada-approved implantable total artificial heart. The product consists of an implantable device, an external pneumatic driver, and drivelines connecting them, designed for biventricular heart replacement. Hospitals and cardiac care centers purchase these systems for patients with end-stage heart failure requiring temporary or permanent heart replacement. The company's revenue model relies on direct sales of the SynCardia TAH system to healthcare institutions specializing in advanced cardiac treatments. SynCardia Systems, LLC focuses on the medical technology segment within the health care equipment and supplies industry, targeting hospitals and medical facilities that perform complex cardiac procedures. The SynCardia TAH is marketed as a life-saving solution for patients with severe heart conditions, with no competing FDA-approved alternatives. The company's revenue stream is derived from the sale of the complete system, including the implant, driver, and drivelines, to healthcare providers who serve patients in critical cardiac care scenarios. The SynCardia TAH system is the sole product line of SynCardia Systems, LLC, with no other medical devices or services offered by the subsidiary. Picard Medical Inc's business model centers on the exclusive distribution of this FDA-approved artificial heart, which is used in both temporary and permanent heart replacement cases. The company's revenue is generated solely through the sale of the SynCardia TAH system to hospitals and cardiac care centers that specialize in treating end-stage heart failure patients. Picard Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Picard Medical stock

FCF Conversion Rate (FCF/EBITDA) of Picard Medical is 58.05 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Picard Medical changed from 56.40 % to 58.05 %, representing a 2.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Picard Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Picard Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Picard Medical

All Key Metrics — Picard Medical